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Protein kinase CK2 (CK2), a constitutively active serine/threonine kinase, is involved in a variety of
roles essential to the maintenance of cellular homeostasis. Elevated levels of CK2 expression results
in the dysregulation of key signaling pathways that regulate transcription, and has been implicated
in cancer. The adenosine-50-triphosphate-competitive inhibitor CX-4945 has been reported to show
broad spectrum anti-proliferative activity in multiple cancer cell lines. Although the enzymatic IC50
of CX-4945 has been reported, the thermodynamics and structural basis of binding to CK2a
remained elusive. Presented here are the crystal structures of human CK2a in complex with
CX-4945 and adenylyl phosphoramidate at 2.7 and 1.3 Å, respectively. Biophysical analysis of
CX-4945 binding is also described. This data provides the structural rationale for the design of more
potent inhibitors against this emerging cancer target.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The focus on small molecule kinase inhibitors in cancer therapy
dramatically increased following the introduction of Imatinib
(Gleevec), a ﬁrst-in-class treatment for chronic myelogenous leu-
kemia, hypereosinophilic syndrome and gastrointestinal stromal
tumors [1]. Research and development programs have traditionally
pursued protein kinases linked to well-validated oncogenic signal
transduction networks. However, comparative whole genome
sequencing of tumor versus normal tissues [2,3] suggests that
the number of cancer associated genes is larger than previously ex-
pected. Targeting kinases beyond the established oncogenic ki-
nome holds signiﬁcant promise for the development of novel
cancer therapies.
Protein kinase CK2 (CK2) (formerly known as casein kinase II)
exists as a tetramer composed of two catalytic (a and a0) and
two regulatory (b and b0) subunits. This serine/threonine kinasechemical Societies. Published by E
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(A.D. Ferguson).is ubiquitously expressed, constitutively active, and has been
shown to play a key role in cell cycle control, cellular differentia-
tion and proliferation [4]. CK2 phosphorylates and regulates the
activity and stability of multiple tumor suppressor proteins, onco-
genes and transcriptional activators [5–7]. Elevated levels or activ-
ity have been observed in multiple cancer types. Recent evidence
suggests that CK2 also acts as a suppressor of apoptosis by phos-
phorylating pro-apoptotic proteins, thereby protecting them from
caspase-mediated cleavage [5]. Decreased CK2 activity either by
antisense oligonucleotide experiments or using the selective small
molecule inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-benz-
imidazole has been shown to reduce cancer cell growth in vitro
and inhibits tumor growth in xenograft models of cancer [8–11].
Interest in developing small molecule inhibitors of CK2 was
heightened with the identiﬁcation of adenosine-50-triphosphate
(ATP)-binding site speciﬁc chemotypes [12–15], the potential for
targeting allosteric sites [16], and the potential for developing
compounds that interfere with heterodimer formation [17,18].
The availability of X-ray crystal structures of human CK2a in the
apo conformation and in complex with small molecule inhibitors
provides an attractive platform for iterative structure-based drug
design [16,18,19]. Recently, a selective CK2a inhibitor with oral
bioavailability designated CX-4945 by Cylene Pharmaceuticals,
entered Phase I clinical trials for advanced solid tumors and multi-
ple myeloma (clinicaltrials.gov identiﬁer: NCT00891280). Welsevier B.V. All rights reserved.
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amidate (AMPPN) in complex with human CK2a at 2.7 and 1.3 Å
resolution, respectively. This represents the highest resolution hu-
man CK2a structure determination to date. This data provides the
structural rationale for the design of more potent inhibitors against
this emerging cancer target.2. Materials and methods
2.1. Reagents
CX-4945 was synthesized and its structure veriﬁed by Merck
Research Laboratories. All nucleotides used in this study were ob-
tained from Sigma, and their purity was found to be >90% by LCMS.
2.2. Expression and puriﬁcation
Residues 2-335 of CK2a was cloned into vector pDEST14 (Invit-
rogen), which encodes an N-terminal His6 tag followed by a TEV
protease cleavage site. The nucleotide sequence was conﬁrmed
by DNA sequencing (Genewiz). CK2a was expressed in Escherichia
coli BL21(DE3) (Novagen) in Terriﬁc Broth supplemented with
50 lg ml1 carbenicillin for 18 h at 16 C with 1 mM IPTG. The cells
were harvested by centrifugation for 15 min at 6000g, pellets
were resuspended in 50 mM Tris pH 8.0, 0.3 M NaCl, 10% glycerol,
1 mM dithiothreitol (DTT), 1 mg ml1 protease inhibitor cocktail III
(EMD Biosciences), and then lysed with a microﬂuidizer. Cell lysate
was clariﬁed by centrifugation at 100 000g for 1 h at 4 C. The
supernatant was ﬁltered and loaded onto a Ni2+-IMAC (Qiagen) col-
umn equilibrated with 50 mM Tris pH 8.0, 0.3 M NaCl, 10% glycerol
and 1 mM DTT. The protein was eluted using an imidazole gradient
(0–0.25 M) containing 50 mM Tris pH 8.0, 0.3 M NaCl, 10% glycerol
and 1 mM DTT. Fractions containing CK2a were pooled and dia-
lyzed overnight against 50 mM Tris pH 8.0, 0.3 M NaCl, 10% glyc-
erol and 1 mM DTT. The N-terminal His6 tag was removed by
adding TEV protease to the dialyzed material using a molar ratio
of 1:100, and the cleavage reaction was allowed to proceed over-
night at 4 C. Cleaved CK2a was then passed over a second Ni2+-
IMAC column to remove uncleaved CK2a and TEV protease. The
ﬂow through was collected, concentrated and further puriﬁed by
size exclusion chromatography using a S75 gel ﬁltration column
(GE Healthcare). Fractions with >95% pure CK2a (as monitored
by SDS–PAGE electrophoresis) were collected and concentrated
to 10 mg ml1 using a centrifugal concentrator. The molecular
weight of CK2a was conﬁrmed by ESI-Ion-Trap-MS using a LTQ-
XL mass spectrometer and the Xcalibur software platform (Ther-
mo-Fisher Scientiﬁc).
2.3. Temperature-dependent ﬂuorescence (TdF)
100 lM CK2a in 25 mM N-(2-hydroxyethyl) piperazine-N0-
(2-ethanesulfonic acid) (HEPES) pH 7.5, 0.15 M NaCl and 1 mM
DTT was thawed on ice, centrifuged for 5 min to remove insoluble
material, and diluted 100-fold. Sypro orange (Invitrogen) was pre-
pared with 100% dimethyl sulfoxide (DMSO). To the 1 lM protein
solution, Sypro orange was added to a ﬁnal concentration of 5X.
CX-4945 was then added at 50 lM (ﬁnal DMSO concentration of
1%). 20 ll samples were pipetted into a white 96-well PCR plate
(Abgene), and sealed with ﬂat ultra clear caps (BioRad).
TdF assays were conducted with a Chromo4 RT-PCR instrument
(MJ Research) equipped with a Peltier block, four LEDs for
illumination, four ﬁltered photodiodes for detection and Opticon
Monitor 2 software. The temperature was increased from 20 to
80 C in 0.2 C increments using a 200 millisecond stabilization de-
lay before reading. Fluorescence signals were acquired with excita-tion and emission wavelengths of 490 nm and 560 nm,
respectively.
A customized analysis program using a non-linear least square
method based on the Generalized Reduced Gradient algorithm
was used to ﬁt the protein unfolding model [20]. The ﬂuorescence
intensity of Sypro orange dye is generally linearly dependent with
temperature. The following parameters were ﬂoated during the ﬁt-
ting process: Y intercepts for the intensity of Sypro orange in both
the native and denatured proteins (Yn and Yd); the associated slopes
(Mn andMd); the midpoint of melting (Tm); and the enthalpy at the
Tm (DHm). The heat capacity at the Tm (DCp) remained constant.
2.4. Temperature-dependent circular dichroism (TdCD)
The relationship between ligand binding and protein stability as
detected by changes in the midpoint of unfolding (Tm) has been
well-documented, and Kd values can be estimated from the DTm
determined by temperature-dependent circular dichroism (TdCD)
[20]. For these measurements, ellipticity was monitored at
227 nm as a function of temperature using a 1 mm cell. A scan rate
of 0.5 C min1 with a four second response time and 30 s equili-
bration between measurements was used. CK2a protein was di-
luted to 10 lM with 25 mM HEPES pH 7.4, 0.15 M NaCl and
1 mM DTT. Ligand binding was tested at 50 lM for CX-4945 and
500 lM for adenylyl-imidodiphosphate (AMPPNP) with a ﬁnal
DMSO concentration of 1%. Jasco software was used to calculate
protein melting temperatures (Tm) and the enthalpy of unfolding
DHu. The reported protein melting temperatures are the average
of two or three independent experiments.
2.5. Isothermal titration calorimetry (ITC)
Puriﬁed CK2a protein was extensively dialyzed against 25 mM
HEPES pH 7.5, 0.3 M NaCl, 5% glycerol and 10 mM b-mercap-
toethanol. The protein concentration was measured using its calcu-
lated extinction coefﬁcient, and was diluted to 15 lMwith dialysis
buffer. 20 mM CX-4945 solubilized in 100% DMSO was diluted to
130 lM using dialysis buffer. CX-4945 was observed to have
>200 lM solubility under these conditions by Nephelometry using
a Nepheloskan Ascent 100 Nephelometer instrument (Labsystems).
For the titration, DMSO was added to the protein solution at the
same percentage as in the compound solution. The ITC experiment
was performed using a VP-ITC titration calorimeter (GE Health-
care). All solutions were thoroughly degassed for 5–10 min at
25 C prior to loading the samples into the ITC cell and syringe.
The titration was carried out at 25 C with a stirring speed of
350 rpm and a 210 s delay between 10 ll injections. Thermody-
namic parameters N (stoichiometry), Ka (association constant)
and DH (enthalpic change) were obtained by non-linear least-
square ﬁtting of the experimental data using a single-site binding
model. The free energy of binding (DG) and entropic change
(DS) were calculated with MicroCal software following equations:
DG = RTlnKa and DG = DH  TDS. The afﬁnity of the protein-
inhibitor complex is represented as the dissociation constant
(Kd = 1/Ka). Titration data was analyzed independently, and the
thermodynamic values obtained were averaged.
2.6. IMAP kinase assay
IMAP technology (Molecular Devices) was used to monitor
substrate phosphorylation activity by CK2a. Phosphorylation of
ﬂuorescently-labeled FAM-CKtide peptides (5-FAM-RRRADDSDD-
DDD-NH2) were assayed in low protein binding 384-well plates.
Each 20 ll well contained IMAP kinase buffer (Molecular Devices),
1 mM DTT, 100 nM FAM-CKtide and 12 nM CK2a. The phosphory-
lation reaction was initiated by the addition of 500 lM ATP and
Table 1
X-ray diffraction data processing and reﬁnement statistics.
Data collection CX-4945 AMPPN
Wavelength (Å) 0.99 1.00
Temperature (K) 100 100
Resolution (Å) 50.0–2.71 30–1.30
Space group P43212 P212121
Unit cell parameters (Å) a = b = 127.64;
c = 125.75
a = 49.38; b = 62.02;
c = 117.06
Number of mol/ASU 2 1
Measured reﬂections 440 492 780 374
Unique reﬂections 28 836 (4123) 89 248 (4392)
Completeness (%) 100 (100) 99.7 (100)
Rmerge (%) 7.2 (49.7) 6.8 (56.6)
‹I/r(I)› 34.2 (6.2) 35.9 (4.3)
Reﬁnement statistics
Resolution (Å) 2.71 (2.81–2.71) 1.30 (1.33–1.30)
Number of reﬂections 28 751 88 667
Number of reﬂections used
for Rfree
1456 4442
Number of protein atoms 5593 3154
Number of heterogen atoms 201 370
Number of water molecules 116 325
Rwork (%) 18.86 16.83
Rfree (%) 21.74 18.66
Average B-factor (Å2) 54.09 16.46
R.m.s. deviations
Bond lengths (Å) 0.01 0.01
Bond angles () 1.04 0.99
Ramachandran distribution
Most favored regions (%) 90.2 89.6
Additional allowed regions
(%)
9.5 10.1
Generously allowed regions
(%)
0.3 0.3
Disallowed regions (%) 0.0 0.0
Values in parentheses are for the highest resolution shell.
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gressive buffer (12% IMAP progression buffer A, 79% IMAP progres-
sion buffer B, and 9% 5 M NaCl). Following overnight incubation,
ﬂuorescence polarization was measured on an Analyst AD instru-
ment (Molecular Devices). Dose-response curves were plotted
from inhibition data generated in duplicate using 8-point serial
dilutions. Dose-response curves were ﬁt to a standard sigmoidal
curve and IC50 values were derived by non-linear regression
analysis.
2.7. Crystallization
2 ll of 10 mg ml1 CK2a protein solution was mixed with an
equal volume of reservoir solution (20–26% PEG 4000, 0.2 M
ammonium sulfate, 0.1 M sodium citrate pH 6, 1 mM MgCl2 and
10 mM AMPPNP). Human CK2a crystallized in three different crys-
tal forms under identical conditions within the same crystalliza-
tion drop. In this case, we observed three different crystal forms
growing under the same conditions with similar morphologies:
P212121 with one molecule in the asymmetric unit; P43212 with
two molecules in the asymmetric unit; and P212121 with four mol-
ecules in the asymmetric unit. High resolution diffraction data for
CK2a in complex with AMPPN was collected from the P212121
crystal form with one molecule in the asymmetric unit. We soaked
several crystals with CX-4945, which turned out to belong to either
space group P43212 with two molecules in the asymmetric unit or
space group P212121 with four molecules in the asymmetric unit.
Although these crystals diffract to lower resolution, the unbiased
electron difference density map allowed for an unambiguous
determination of the binding mode, hence we did not screen fur-
ther. The co-structure with CX-4945 presented in this manuscript
belongs to space group P43212 with two molecules in the asym-
metric unit. Although not presented in this manuscript, the struc-
ture of CK2a in complex with CX-4945 in space group P212121 is
identical within the experimental errors. Crystallization was per-
formed by the hanging drop vapor diffusion method at 18 C. Crys-
tals appeared overnight and grew to typical dimensions of
approximately 0.1  0.1  0.2 mm. CX-4945 was introduced into
pre-grown CK2a-AMPPNP crystals by soaking for 2 days at 18 C
in mother liquor containing 1 mM CX-4945.
2.8. Data collection, structure determination and reﬁnement
Prior to freezing in liquid nitrogen, crystals were brieﬂy soaked
in a solution containing mother liquor and 20% glycerol. Diffraction
data was collected at 100 K on the IMCA beam line at the Advanced
Photon Source. Data were indexed and scaled using HKL2000 [21],
XDS [22] and SCALA from the CCP4 suite [23]. Initial phases were
determined using Molrep [24] using the unliganded human CK2a
kinase domain as the search model. Model building and reﬁnement
were completed using Coot [25] and BUSTER [26]. The structure
was reﬁned using anisotropic temperature factors. The ﬁnal statis-
tics are summarized in Table 1. The coordinates and structure fac-
tor amplitudes for CK2a in complex with CX-4945 and AMPPN
have been deposited in the Protein Data Bank with accession codes
PDB ID: 3NGA and PDB ID: 3NSZ, respectively. All structural ﬁgures
were produced using PyMOL (Schrödinger, LLC).3. Results and discussion
3.1. Puriﬁcation, activity and biophysical characterization of CX-4945
binding
Human CK2a was expressed and puriﬁed to >95% homogeneity
using methods similar to those described previously [27]. PuriﬁedCK2a was capable of phosphorylating a peptide sequence known
to be a substrate of this kinase (see Section 2). As previously re-
ported [28], the dose-dependent binding curves for CX-4945
(Fig. 1a) inhibition of CK2a revealed that it is a potent inhibitor
with an IC50 of 13 nM (Fig. 1b).
While the IC50 for CX-4945 was known [28], its corresponding
dissociation constant value remained to be determined. To mea-
sure direct binding parameters for CX-4945, temperature-
dependent ﬂuorescence (TdF), temperature-dependent circular
dichroism (TdCD) and isothermal calorimetry (ITC) methods were
used. Our TdF assay utilized Sypro orange as the ﬂuorescent probe.
Sypro orange is an environmentally friendly dye that has low
quantum yields in an aqueous environment, but is highly ﬂuores-
cent in non-polar environments with low dielectric constants, such
as hydrophobic areas within proteins. If a protein is largely folded
and has no surface exposed hydrophobic patches, there will be low
ﬂuorescence emission at room temperature. Protein unfolding as a
function of temperature would expose buried hydrophobic patches
resulting in a signiﬁcant increase in ﬂuorescence emission. The
midpoint of the folding-unfolding transition provides the DTm va-
lue. In the presence of 50 lM CX-4945, CK2a showed a large stabi-
lizing shift in Tm relative to apo protein of approximately 16 C
(Fig. 1c and Table 2).
In this TdF assay, ﬂuorescence is dependent on binding of Sypro
orange to hydrophobic sites on the protein. It is conceivable that
the dye binding equilibrium could impact the DTm measurement.
To eliminate this possibility, we also determined the Tm value of
CK2a using TdCD (Fig. 1d). The TdCD assay is free of dye artifacts
as the thermal denaturation monitoring probe in TdCD is intrinsic
to the protein (circular dichroism signal from proteins secondary
structure). These results clearly show that puriﬁed CK2a loses sec-
Fig. 1. (a) Chemical structure of CX-4945. (b) IMAP assay in which kinase activity was measured in the presence of increasing concentrations of CK-4945. (c) Unfolding of
CK2a as monitored by TdF in the absence (d) and presence (N) of CX-4945. Buffer conditions: 25 mM HEPES pH 7.5, 0.15 M NaCl and 1 mM DTT. (c) Unfolding of CK2a as
monitored by TdCD for absence (d), and presence of AMPPNP () and CX-4945 (N). Buffer conditions: 25 mMHEPES pH 7.4, 0.15 M NaCl and 1 mMDTT. (e) Raw (upper panel)
and ﬁtted ITC data for sequential CX-4945 titrations plotted versus the molar ratio of titrant/protein (lower panel). Buffer conditions: 25 mM Hepes pH 7.5, 0.3 M NaCl, 5%
glycerol and 10 mM b-mercaptoethanol.
Table 2
Thermal shift data for CX-4945 binding.
TdF TdCD ITC IMAP
Tm
(C)
DTm
(C)
Tm
(C)
DTm
(C)
Kd
(nM)
DH
(kcal mol1)
TDS
(kcal mol1)
IC50
(nM)
Apo 39.2 – 37.6 – – – – –
CX-4945 55.2 16 56.5 18.9 <10 13.6 2.3 13
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moidal fashion as expected for a native-like protein that unfolds
cooperatively (Fig. 1d). The binding of 50 lM CX-4945 to CK2a also
resulted in a large DTm shift of 18.9 C (Fig. 1d and Table 2).
On the basis of these thermal denaturation results, ITC binding
studies were also performed to obtain a more complete thermody-namic analysis of CX-4945 binding to CK2a (Fig. 1e). The exother-
mic evolution of heat following sequential injections of inhibitor
illustrates saturatable inhibitor binding. Analysis of the enthalpic
change versus the molar ratio of CK2a to CX-4945 (lower panel) re-
vealed an apparent Kd of <10 nM for CX-4945 (Table 2). A compar-
ison of the DH and TDS shows that CX-4945 binding to CK2a is
108 A.D. Ferguson et al. / FEBS Letters 585 (2011) 104–110predominantly enthalpic with some entropic penalty (Table 2). Ta-
ken together these results conﬁrm and extend the previous report
indicating that CX-4945 is a potent inhibitor of CK2.
3.2. Structure of CK2a in complex with CX-4945 and AMPPN
Human CK2a crystallized in three different crystal forms under
identical conditions within the same crystallization drop (see Sec-
tion 2.7). The diffraction properties of these crystal forms differ sig-
niﬁcantly, and we choose to present the two highest resolution
structures (Table 1). The P43212 crystal form was used for CX-
4945 in this study, and the structure was solved using molecular
replacement and the ﬁnal model was reﬁned to Rwork and Rfree val-
ues of 18.8% and 21.8%, respectively. The AMPPN bound structure
belongs to space group P212121 with one molecule in the asym-
metric unit, and the ﬁnal model was reﬁned to Rwork and Rfree val-
ues of 16.8% and 18.7%, respectively. Data collection, reﬁnement
and Ramachandran statistics for both structures are shown in Ta-
ble 1.
The crystal structure of human CK2a in complex with CX-4945
was determined at 2.7 Å resolution (Fig. 1a and Table 1). Bound
within the ATP-binding site of CK2a is a single CX-4945 molecule
with clear electron density in each protein monomer (Fig. 2). No
signiﬁcant differences were observed between the ATP-binding
sites between monomers. CX-4945 forms two direct protein-inhib-
itor hydrogen bonds with CK2a. The pyridine group of CX-4945
interacts with the nitrogen atom in the backbone of residue
V116 (2.7 Å) from the hinge region, and the carboxylate substitu-
ent of CX-4945 interacts with the amino group of residue K68
(2.9 Å) from b3 strand of CK2a. The carbonyl oxygen atom of resi-
due V116 from the interdomain hinge region is placed more than
3.5 Å away from the pyridine nitrogen of CX-4945, and therefore,
does not contribute to inhibitor binding. Two well-ordered water
molecules (W1 and W2) mediate additional protein-inhibitor con-
tacts between the carboxylate group of CX-4945 and CK2a. Water
molecule W1 bridges interactions between the carboxylate of res-
idue E81 (2.5 Å) from helix aC and the nitrogen atom in the back-
bone of residue W176 from the activation segment (2.8 Å). A
second water molecule W2 mediates an interaction with the car-
boxylate of residue D175 from the activation segment (3.1 Å). Res-
idues K68 and D175 are highly conserved and are both essential forFig. 2. The binding site of human CK2a in complex with CX-4945. CX-4945 is shown as
chlorine atoms. The ﬁnal 2Fo–Fc electron density map surrounding the inhibitor is sh
interactions with CX-4945 are shown as sticks with white carbon atoms, blue nitrogen at
site are shown as red spheres. The protein backbone is shown as a white ribbon.the enzymatic activity of CK2a. The glycine-rich loop of CK2a is
placed on top of the CX-4945 molecule. The rigid conformation
of CX-4945 may confer a small entropic penalty in binding to
CK2a. However, the planar three ring structure of CX-4945
(Fig. 1a) would likely gain enthalpy from van der Waals contacts
with the hydrophobic residues V53, V66, I95, F113, H160, M163
and I174 which form the ATP-binding site. Collectively, this exten-
sive combination of direct and water-mediated hydrogen bonds
and van der Waals contacts observed between CX-4945 and
CK2a establishes the structural basis for the high afﬁnity binding
for this small molecule inhibitor.
The high resolution crystal structure of human CK2a in complex
with the ATP analogue AMPPN was also determined at 1.3 Å reso-
lution (Table 1), which represents the highest resolution structure
determined for human CK2a to date and the ﬁrst with this small
molecule [27]. Under these crystallization conditions (slightly
acidic at pH 6), AMPPNP is chemically unstable and can rapidly
hydrolyze to AMPPN and inorganic phosphate. Our structural
observations support the hydrolysis of AMPPNP to AMPPN as the
expected c-phospharyl of AMPPNP was not visible in the electron
density map and could not be modeled. We conclude that we have
crystallized CK2a in complex with AMPPN. Residue Y50 located at
the tip of the glycine-rich loop packs against the phosphoramidate
group of the AMPPN molecule. As expected, one AMPPN molecule
with two coordinating Mg2+ ions is bound in the ATP-binding site
of the kinase (Fig. 3). The coordination and positions of the Mg2+
ions with respect to AMPPN are similar are previously described
for AMPPNP [19]. A series of positively-charged residues, two
Mg2+ ions and residues K68 and K158 are required to balance the
negatively-charged diphosphate moiety of AMPPN. To compare
the binding modes of CX-4945 and AMPPN the reﬁned coordinates
for both complexes were superimposed with an overall root mean
square deviation of 0.7 Å ﬁtted over 327 Ca atoms (Fig. 4) [29]. This
comparison reveals that the hinge binding element of CX-4945
occupies a similar position to the purine component of AMPPN.
The mono-chlorinated phenyl group is placed near the ribose,
whereas the carboxylate moiety of CX-4945 is positioned at the
a-phosphate of AMPPN.
Two dynamic regions of CK2a, the b4/b5 loop that is part of the
CK2a/CK2b interface and the interdomain hinge, have been deﬁned
[18,19]. In the CX-4945 and AMPPN bound structures, this regionsticks with yellow carbon atoms, blue nitrogen atoms, red oxygen atoms, and green
own as blue mesh (contoured at 1r). Protein side chains that form electrostatic
oms, and red oxygen atoms. Two well-ordered water molecules found in the binding
Fig. 4. Comparing the binding modes of CX-4945 and AMPPN. The CX-4945
molecule is shown as sticks with white carbon atoms, blue nitrogen atoms, red
oxygen atoms, and green chlorine atoms. The AMPPN molecule is shown as sticks
with green carbon atoms, blue nitrogen atoms, red oxygen atoms, and orange
phosphorous atoms. The CX-4945 and AMPPN bound conformations of CK2a are
shown as white and green ribbons, respectively.
Fig. 3. The binding site of human CK2a in complex with AMPPNP. The AMPPNP molecule is shown as sticks with yellow carbon atoms, blue nitrogen atoms, red oxygen
atoms, and orange phosphorous atoms. The ﬁnal 2Fo–Fc electron density map surrounding the AMPPN molecule is shown as blue mesh (contoured at 1r). Protein side chains
composing the hinge region are shown as sticks with white carbon atoms, blue nitrogen atoms, and red oxygen atoms. Two coordinated Mg2+ ions are shown as green
spheres. The protein backbone is shown as a white ribbon.
A.D. Ferguson et al. / FEBS Letters 585 (2011) 104–110 109expectedly adopts the closed conformation. The interdomain hinge
region is also observed in the active conformation in both struc-
tures (Fig. 4).
In conclusion, thermal denaturation and calorimetric methods
were used to fully characterize the binding of CX-4945 to CK2a.
We determined the crystal structures of the catalytic subunit of
human CK2a in complex with CX-4945 and AMPPNP, and de-
scribed the orientation of these small molecules within the ATP-
binding site. These structural details provide a platform from
which to develop new inhibitors that are capable of better exploit-
ing interactions with the interdomain hinge and other regions of
CK2a, and therefore, generate a lead with greater binding afﬁnity
and kinase speciﬁcity.Acknowledgements
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